~~<i id='049F13D586'><strike id='049F13D586'><tt id='049F13D586'><pre id='049F13D586'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

leisure time

author：leisure time 2025-10-03 00:40:58 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

MoonLake Immunotherapeutics, a Swiss biotech, was buried Monday under an avalanche of its own data spin.

It’s been awhile since I encountered a management team that speaks so arrogantly about the supposed supremacy of its own drug, but then fails to back up the talk with real data. MoonLake claimed its experimental antibody called sonelokimab delivered “landmark” results in a mid-stage study of psoriatic arthritis.

Landmark? That’s a strange way of describing the results of a clinical trial that showed sonelokimab topping a placebo — an easy hurdle — but failing to separate from an active treatment comparator, the generic drug adalimumab (known better as Humira).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Kaiser's Risant Health gobbled up Geisinger. Who is next?

knowledge

focus

explore

focus

entertainment

AdobeCHICAGO—Comfortcanbedeliveredtopatientswithadvancedcancervirtuallyjustaswellasinperson,accordin

WSS

Maker of FluMist seeks to allow at

Telehealth options flood the market as retailers push virtual care

Intellia reports positive results for its CRISPR

Testing for cancer recurrence creates a new limbo for patients

FDA has safety concerns on CRISPR

Biden's order seeks to regulate AI risk without stifling innovation

Wikipedia

leisure time

knowledge

Medicare details structure of new drug price negotiation program

NIH documents show early flaws of $1.6 billion long Covid program

Jerome Adams on the need for new antivirals for Covid

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

DIEP, the 'gold standard' of breast reconstruction, is under threat

Emergency medicine has repudiated 'excited delirium.' Now what?

Medicare proposal to cover medical devices draws a mixed reaction

Ultragenyx gene therapy for rare liver ailment succeeds in late

Dobbs anniversary: the lost opportunity of abortion as health care

The pink breast cancer awareness ribbon needs a redesign

focus

The Pandemic Treaty must support building strong health systems

Telehealth options flood the market as retailers push virtual care

The Pandemic Treaty must support building strong health systems

With trial win, GSK could get blood cancer drug back on market

Shifting the focus from loneliness to social health

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

focus

explore

focus

entertainment